FindTrial
Sign In

Pyrotinib Maleate

DRUG8 trials

Sponsors

Guangdong Association of Clinical Trials, Jiangsu HengRui Medicine Co., Ltd., Tianjin Medical University Cancer Institute and Hospital, Zhongshan Hospital Xiamen University, Henan Cancer Hospital

Conditions

Breast NeoplasmsCarcinoma, Non-Small-Cell LungHER2 Mutant Non-small Cell Lung CancerHER2-positive Advanced Breast CancerHER2-positive Breast CancerHealthy ParticipantsHealthy Subjects, Drug-drug Interaction, PyrotinibSolid Tumor

Phase 1

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
CompletedNCT04315116
Jiangsu HengRui Medicine Co., Ltd.Healthy Participants
Start: 2020-04-13End: 2020-09-01Updated: 2022-10-28
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
NCT04680091
Jiangsu HengRui Medicine Co., Ltd.Healthy Subjects, Drug-drug Interaction, Pyrotinib
Start: 2020-11-12End: 2021-12-30Updated: 2021-04-22

Phase 2

Phase II Umbrella Study Directed by Next Generation Sequencing
NCT03574402
Guangdong Association of Clinical TrialsCarcinoma, Non-Small-Cell Lung
Start: 2018-07-09End: 2024-12-30Target: 400Updated: 2022-12-06
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
CompletedNCT04903652
Tianjin Medical University Cancer Institute and HospitalHER2-positive Advanced Breast Cancer
Start: 2021-01-01End: 2022-02-06Updated: 2022-04-07
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
NCT05274191
Zhongshan Hospital Xiamen UniversitySolid Tumor
Start: 2022-03-04End: 2024-03-15Target: 60Updated: 2022-03-10
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
NCT05328440
Henan Cancer HospitalBreast Neoplasms
Start: 2022-05-20End: 2026-01-01Target: 120Updated: 2023-09-25
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Active, not recruitingNCT05426486
Caigang LiuHER2-positive Breast Cancer
Start: 2022-05-23End: 2028-12-30Target: 136Updated: 2024-10-30

Unknown Phase

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2
NCT05411276
Beijing Chest HospitalHER2 Mutant Non-small Cell Lung Cancer
Start: 2022-06-30End: 2024-12-31Target: 15Updated: 2022-06-09

Related Papers

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.
2025-07-012 citations
Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial.
2023-10-0710 citations
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.
2023-09-227 citations
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
2023-07-2439 citations
Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.
Journal of Clinical Oncology2022-06-011 citations